⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772328 | 0.85 | — | — | |
| SCHEMBL24679 | 0.80 | — | — | |
| SCHEMBL26241 | 0.75 | — | — | |
| SCHEMBL115508 | 0.75 | — | — | |
| SCHEMBL26145 | 0.72 | — | — | |
| SCHEMBL2010848 | 0.72 | — | — | |
| SCHEMBL1678761 | 0.72 | ALDH1A1 (0.45) | — | |
| SCHEMBL9206593 | 0.72 | ALDH1A1 (0.45) | — | |
| SCHEMBL2109467 | 0.72 | ALDH1A1 (0.45) | — | |
| SCHEMBL245390 | 0.72 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389746-A2 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2024-06-26 | — | — | EP | claimed |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | claimed |
| US-11999732-B2 | P2X3 receptor antagonists | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-04 | — | — | US | claimed |
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | claimed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | claimed |
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2021-08-12 | — | — | US | claimed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | claimed |
| EP-3820566-A1 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2021-05-19 | — | — | EP | claimed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| CN-112584898-A | P2X3Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2009133387-A1 | INDOLE- 3 -GLYOXYLAMIDE DERIVATIVES FOR USE AS CALCIUM ION CHANNEL MODULATORS | LECTUS THERAPEUTICS LIMITED (GB) | 2009-11-05 | — | — | WO | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| EP-0885227-A1 | PYRIMIDO 5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032882-A1 | PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | claimed |